ArticleBMC pulmonary medicine2025

Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report.

Kenta Manabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.